Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[seek the light]

Science IP is valuable!!!

6:36 am AstraZeneca and Eli Lilly (LLY) announce alliance to develop and commercialise BACE inhibitor AZD3293 for Alzheimer's disease; LLY will pay AZN up to $500 mln in development and regulatory milestone payments (AZN) : Co and Eli Lilly (LLY) announced an agreement to jointly develop and commercialise AZD3293, an oral beta secretase cleaving enzyme inhibitor currently in development as a potential treatment for Alzheimer's disease.

•Under the terms of the agreement, Lilly will pay AstraZeneca up to $500 million in development and regulatory milestone payments.
•AstraZeneca expects to receive the first milestone payment of $50 million in the first half of 2015.
•The co will share all future costs equally for the development and commercialisation of AZD3293, as well as net global revenues post-launch.